2023
Delta‐9‐tetrahydrocannabinol modulates pain sensitivity among persons receiving opioid agonist therapy for opioid use disorder: A within‐subject, randomized, placebo‐controlled laboratory study
De Aquino J, Meyerovich J, Xie C, Ranganathan M, Compton P, Pittman B, Rogan M, Sofuoglu M. Delta‐9‐tetrahydrocannabinol modulates pain sensitivity among persons receiving opioid agonist therapy for opioid use disorder: A within‐subject, randomized, placebo‐controlled laboratory study. Addiction Biology 2023, 28: e13317. PMID: 37644897, PMCID: PMC10468603, DOI: 10.1111/adb.13317.Peer-Reviewed Original ResearchConceptsOpioid use disorderOpioid agonist therapyAgonist therapyMethadone dosesMethadone therapyPain sensitivityUse disordersPlacebo-controlled laboratory studySynergistic antinociceptive effectCognitive adverse effectsSingle oral dosesRisk-benefit profilePain sensitivity measuresCannabinoid receptor systemAntinociceptive effectTHC doseOral dosesOpioid agonistsAcute effectsCannabinoid agonistsPreclinical studiesAbuse potentialOpioid crisisTherapyReceptor system
2020
Rapid Transition From Methadone to Buprenorphine Utilizing a Micro-dosing Protocol in the Outpatient Veteran Affairs Setting.
De Aquino J, Fairgrieve C, Klaire S, Garcia-Vassallo G. Rapid Transition From Methadone to Buprenorphine Utilizing a Micro-dosing Protocol in the Outpatient Veteran Affairs Setting. Journal Of Addiction Medicine 2020, 14: e271-e273. PMID: 32011408, PMCID: PMC7392785, DOI: 10.1097/adm.0000000000000618.Peer-Reviewed Original ResearchConceptsOpioid use disorderPrecipitated withdrawalTreatment of opioid use disorderCessation of methadoneMicro-dose protocolRisk of precipitated withdrawalMethadone to buprenorphineOpioid agonist therapyTransition to buprenorphineAgonist therapyOpioid useOutpatient protocolUse disorderOutpatient settingVeterans Affairs settingsBuprenorphineMethadonePsychiatry settingWithdrawalTransition protocolDemonstrating feasibilityInductionOpioidTherapyPatients